Lung Cancer News and Research

Latest Lung Cancer News and Research

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international multicentre clinical program of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

4 Jun 2014

Lung cancer patient's blood sample can help predict treatment response

Scientists have shown how a lung cancer patient's blood sample could be used to monitor and predict their response to treatment - paving the way for personalised medicine for the disease.

3 Jun 2014

Public health issues often ignored in many transportation projects

A new study from the University of Colorado Denver shows public health issues are often ignored in many transportation projects, especially when major roads are built through lower-income neighborhoods.

3 Jun 2014

Variations in BRCA2 and CHEK2 genes can increase lung cancer risk, study finds

New research confirms a vulnerability to lung cancer can be inherited and implicates the BRCA2 gene as harboring one of the involved genetic mutations.

3 Jun 2014

Oncologists urged to consider financial impact of treatments

The American Society of Clinical Oncology is developing a system to rate drugs for advanced cancer based on their likely benefits and side effects, as well as on their price. Meanwhile, better long-term care is urged for the millions who survive the disease and a report details how drugmakers are tailoring treatments to individuals' genetic makeups even though that may affect only small numbers of people.

3 Jun 2014

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

Aduro BioTech, Inc., a clinical stage biotechnology company, today announced the presentation of safety and efficacy data from a Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with standard chemotherapy in patients with unresectable malignant pleural mesothelioma.

2 Jun 2014

First Edition: June 2, 2014

Today's headlines include reports about state health law implementation activities as well as the next steps regarding the difficulties at the VA health system.

2 Jun 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

$Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma$

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine.

2 Jun 2014

BRCA2 gene doubles lung cancer risk among smokers

Around a quarter of smokers who carry a defect in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals.

2 Jun 2014

Volatile organic compounds in exhaled breath show presence and stage of lung cancer

Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.

2 Jun 2014

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-β).

31 May 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago.

31 May 2014

$ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM$

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago.

31 May 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., today announced expansion of the UltraSEEK™ technology, the first ultrasensitive somatic mutation detection technology for high-throughput and definitive interrogation of rare mutations that occur at less than 1% abundance in matched tissue, circulating plasma, and tumor samples.

31 May 2014

Researchers develop virtual platform that measures level of addiction of smokers

In Mexico, 21.7 percent of the population smokes, which is associated with 95 percent of  lung cancer cases and the development of 29 more different conditions.

31 May 2014

EKF, GILUPI report data on circulating tumour cell DNA enrichment, mutation detection

EKF and GILUPI, announce results from collaborative work using GILUPI CellCollector and EKF Molecular’s PointMan DNA Enrichment technology.

From EKF Diagnostics 30 May 2014

UT Southwestern researchers identify protein critical to the spread of deadly cancer cells

UT Southwestern Medical Center cancer researchers have identified a protein critical to the spread of deadly cancer cells and determined how it works, paving the way for potential use in diagnosis and eventually possible therapeutic drugs to halt or slow the spread of cancer.

29 May 2014

New nanoscale structures capable of introducing "cocktail" of multiple drugs into cancer cells

Biomedical engineering researchers have developed daisy-shaped, nanoscale structures that are made predominantly of anti-cancer drugs and are capable of introducing a "cocktail" of multiple drugs into cancer cells.

29 May 2014

Lung Cancer News and Research

Latest Lung Cancer News and Research

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

Lung cancer patient's blood sample can help predict treatment response

Public health issues often ignored in many transportation projects

Variations in BRCA2 and CHEK2 genes can increase lung cancer risk, study finds

Oncologists urged to consider financial impact of treatments

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

First Edition: June 2, 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

BRCA2 gene doubles lung cancer risk among smokers

Volatile organic compounds in exhaled breath show presence and stage of lung cancer

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Researchers develop virtual platform that measures level of addiction of smokers

EKF, GILUPI report data on circulating tumour cell DNA enrichment, mutation detection

UT Southwestern researchers identify protein critical to the spread of deadly cancer cells

New nanoscale structures capable of introducing "cocktail" of multiple drugs into cancer cells

The ultimate guide to lung research tools and protocols eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in